A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Conditions
Metastatic Hepatocellular Carcinoma · Local Advanced Hepatocellular Carcinoma · Alpha-fetoprotein (AFP)-Producing Gastric Cancer · Extragonadal Yolk Sac Tumors · Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope Phoenix Cancer Center, Goodyear, Arizona, United States
City of Hope National Medical Center, Duarte, California, United States
City of Hope Chicago Cancer Center, Zion, Illinois, United States
Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States
Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh, Pennsylvania, United States
Scri Oncology Partners, Nashville, Tennessee, United States
The University of Texas Md Anderson Cancer Center, Houston, Texas, United States
Centro Gaucho Integrado de Oncologia Hospital Mae de Deus, Porto Alegre, Brazil
Hospital Da Bahia, Salvador, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto, São José do Rio Preto, Brazil
Anhui Provincial Hospital, Hefei, Anhui, China
Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Guangxi Medical University Cancer Hospital Wuxiang Branch, Nanning, Guangxi, China
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Hunan Cancer Hospital, Changsha, Hunan, China
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
The Second Affiliated Hospital of Nanchang Universityhongjiaozhou Branch, Nanchang, Jiangxi, China
Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Lishui Central Hospital, Lishui, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Hopital Beaujon, Clichy, France
Centre Hospitalier Universitaire Nantes Hotel Dieu, Nantes, France
Institut Gustave Roussy, Villejuif, France
Irccs Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
Iov Istituto Oncologico Veneto Irccs, Padova, Italy
Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy
Irccs Humanitas Research Hospital, Rozzano, Italy
Kindai University Hospital, Sakai, Osaka, Japan
Tokyo Metropolitan Komagome Hospital, Bunkyoku, Tokyo, Japan
Cancer Institute Hospital of Jfcr, Kotoku, Tokyo, Japan
Auckland City Hospital, Auckland, New Zealand
Hospital Oncologico, Rio Piedras, Puerto Rico
Chungbuk National University Hospital, Cheongju-si, Chungcheongbukdo, South Korea
Cha Bundang Medical Center, Cha University, BundangGu SeongnamSi, Gyeonggi-do, South Korea
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea
Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi, South Korea
Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi, South Korea
Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, South Korea
Asan Medical Center, SongpaGu, Seoul Teugbyeolsi, South Korea
Study leads
Study Director
BeOne Medicines